Robyn Cheuk

Robyn Cheuk

Auto-generated profile, based on publicly available information

Robyn Cheuk

Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2001 in Cancer
Verified
Journal Article
Open access
PDF file
AOAndreas Obermair
Andreas Obermair
RCRobyn Cheuk
Robyn Cheuk
KHKeith Horwood
Keith Horwood
MJMonika Janda
Monika Janda
BBBarbara Bachtiary
Barbara Bachtiary
ACAlex J. Crandon
Alex J. Crandon
BACKGROUND In patients undergoing radiation for cervical carcinoma, there is evidence that anemia is associated with an impaired outcome. For patients undergoing chemoradiation, there are no data available. The objective of this retrospective study was to examine the impact of anemia before and during chemoradiation in patients with cervical carcinoma. METHODS The authors collected data on hemoglobin (Hb) levels before and during treatment from 57 patients with cervical carcinoma. The stage of disease ranged between Stage IB and Stage IVA. All patients were treated with concurrent chemoradiation. Response to chemoradiation was evaluated by univariate and multivariate analyses. RESULTS The mean Hb level at the time of presentation was 12.9 ± 1.6 g/dL in patients with a complete clinical response (CCR) and 12.1 ± 1.4 g/dL in those with persistent disease (P = 0.126). In patients with a CCR, the mean nadir Hb level was 11.1 ± 1.3 g/dL, and in patients with treatment failure, it was 9.8 ± 1.8 g/dL (P = 0.008). A univariate logistic regression model demonstrated that the nadir Hb level was the most predictive factor for treatment failure (relative risk, 1.92; P = 0.015) followed by disease stage (relative risk, 0.51; P = 0.074). In a multivariate model, the nadir Hb level remained the only prognostically relevant factor predicting the response to chemoradiation. Only patients with nadir Hb values > 11 g/dL throughout chemoradiation had a more than 90% chance of achieving a CCR. CONCLUSIONS In patients undergoing chemoradiation for cervical carcinoma, the nadir Hb level is highly predictive of response to treatment, whereas the Hb level at the time of presentation is prognostically not significant. Cancer 2001;92:903–8. © 2001 American Cancer Society.

1 September 2003 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
AOA. Obermair
A. Obermair
RCR. Cheuk
R. Cheuk
KHK. Horwood
K. Horwood
MNM. Neudorfer
M. Neudorfer
MJMonika Janda
Monika Janda
ACA.J. Crandon
A.J. Crandon

31 July 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
RCRaymond J. Chan
Raymond J. Chan
JKJacqui Keller
Jacqui Keller
RCRobyn Cheuk
Robyn Cheuk
RBRae Blades
Rae Blades
LTLee Tripcony
Lee Tripcony
SKSamantha Keogh
Samantha Keogh
Radiation-induced skin reaction (RISR) is one of the most common and distressing side effects of radiotherapy in patients with cancer. It is featured with swelling, redness, itching, pain, breaks in skin, discomfort, and a burning sensation. There is a lack of convincing evidence supporting any single practice in the prevention or management of RISR.

17 February 2012 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Closed access
PDF file
CHCarmen J Hansen
Carmen J Hansen
LKLiz Kenny
Liz Kenny
SLSunil Lakhani
Sunil Lakhani
OUOwen Allen Ung
Owen Allen Ung
JKJacqui Keller
Jacqui Keller
JMJarad Martin
Jarad Martin

22 April 2022 in Journal of Medical Radiation Sciences
Verified
Journal Article
Open access
MNMinh Nguyen
Minh Nguyen
TDThu Dang
Thu Dang
LDLiz Deegan
Liz Deegan
KHKelsie Henry
Kelsie Henry
SJScott Jones
Scott Jones
CHCatriona Hargrave
Catriona Hargrave
Introduction: Paediatric patients (individuals below 18 years of age) requiring cranial‐spinal irradiation (CSI) at our institution are commonly planned and treated using a three isocentre (3‐ISO) volumetric modulated arc therapy (VMAT) technique. A modified two isocentre (2‐ISO) VMAT technique was investigated with the aim to improve workflow and reduce planning and treatment time.Methods: Five CSI paediatric patients previously treated with a 3‐ISO VMAT technique were retrospectively replanned using a 2‐ISO VMAT technique. The 2‐ISO VMAT plans were reviewed and approved by a radiation oncologist (RO) before undergoing patient‐specific quality assurance (QA) procedures, performed by a radiation oncology medical physicist (ROMP). Planning target volume (PTV) coverage, organ‐at‐risk (OAR) dose as well as planning and treatment durations of the first five patients utilising 2‐ISO technique were compared with 3‐ISO technique.Results: The average percentage difference in PTV coverage by 95% reference dose between the 2‐ISO and 3‐ISO is 0.14%, and the average difference in OAR median dose is 0.68 Gy. Conformity and homogeneity indices have the same averages at 1.18 and 0.4 respectively. Patient‐specific physics QA results were all comparable with the 3‐ISO averages at 98.84% and the 2‐ISO at 98.71%. Planning duration for the 2‐ISO was reduced by up to 75%, and daily treatment duration was reduced by up to 50%. Of all the previously treated CSI patients using a 3‐ISO technique, 45% were suitable for the 2‐ISO technique.Conclusion: The 2‐ISO VMAT technique provided comparable dose distribution based on PTV coverage, OAR dose and plan metric indices. Reduced planning and treatment duration with the 2‐ISO technique facilitated improved workflow with decreased sedation time for paediatric patients requiring a general anaesthesia.

26 February 2001 in Australasian Radiology
Verified
Journal Article
Closed access
PDF file
CMCraig MacLeod
Craig MacLeod
RCRobyn Cheuk
Robyn Cheuk
MDMike Dally
Mike Dally
AFAllan Fowler
Allan Fowler
SGStan Gauden
Stan Gauden
PJPeter Jeal
Peter Jeal